findmyKOL
Clinical trialNCT02026349CompletedPhase 3Interventional

Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults - T705US316

SponsorMDVI, LLCEnrollment860Influenza
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

225 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia
  • Facility name not stated

    Bedford Park, South Australia, Australia

Belgium
  • Facility name not stated

    Deurne, Antwerpen, Belgium

  • Facility name not stated

    Brussels, Brussels Capital, Belgium

  • Facility name not stated

    Gozée, Hainaut, Belgium

  • Facility name not stated

    Mont-sur-Marchienne, Hainaut, Belgium

  • Facility name not stated

    Halen, Limburg, Belgium

  • Facility name not stated

    Ham, Limburg, Belgium

  • Facility name not stated

    Chenée, Liège, Belgium

  • Facility name not stated

    Deurne, Belgium

  • Facility name not stated

    Gribomont, Belgium

  • Facility name not stated

    Linkebeek, Belgium

Bulgaria
  • Facility name not stated

    Gabrovo, Gabrovo, Bulgaria

  • Facility name not stated

    Haskovo, Haskovo, Bulgaria

  • Facility name not stated

    Plovdiv, Plovdiv, Bulgaria

  • Facility name not stated

    Smolyan, Smolyan, Bulgaria

  • Facility name not stated

    Sofia, Sofia-Grad, Bulgaria

  • Facility name not stated

    Varna, Varna, Bulgaria

  • Facility name not stated

    Veliko Tarnovo, Veliko Tarnovo, Bulgaria

  • Facility name not stated

    Burgas, Bulgaria

  • Facility name not stated

    Burgas, Bulgaria

  • Facility name not stated

    Gabrovo, Bulgaria

  • Facility name not stated

    Plovdiv, Bulgaria

  • Facility name not stated

    Plovdiv, Bulgaria

  • Facility name not stated

    Rousse, Bulgaria

  • Facility name not stated

    Rousse, Bulgaria

  • Facility name not stated

    Samokov, Bulgaria

  • Facility name not stated

    Sevlievo, Bulgaria

  • Facility name not stated

    Sliven, Bulgaria

  • Facility name not stated

    Smolyan, Bulgaria

  • Facility name not stated

    Sofia, Bulgaria

  • Facility name not stated

    Sofia, Bulgaria

  • Facility name not stated

    Sofia, Bulgaria

  • Facility name not stated

    Sofia, Bulgaria

  • Facility name not stated

    Sofia, Bulgaria

  • Facility name not stated

    Sofia, Bulgaria

  • Facility name not stated

    Varna, Bulgaria

  • Facility name not stated

    Veliko Tarnovo, Bulgaria

Hungary
  • Facility name not stated

    Balassagyarmat, Hungary

  • Facility name not stated

    Budapest, Hungary

  • Facility name not stated

    Csongrád, Hungary

185 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Jan 2014
Primary completion
31 Mar 2015
Completion
31 Mar 2015
Last update posted
11 Nov 2015
Registered enrollment
860
Registry id
NCT02026349

Cross-registrations

EU-CTR / CTIS (EudraCT)2013-002149-13

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.